Table 3 Estimated median iNMB (in million CDN$) and 95% credible intervals [CrI] of the mean iNMB values for comparing each testing program with the baseline scenario of testing only severe cases, and with timelines corresponding to scenarios in Fig. 2
From: Economic evaluation of COVID-19 rapid antigen screening programs in the workplace
Booster coverage | Duration of the screening program in weeks | Testing program | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
0 to 16 | 0 to 32 | 0 to 52 | 16 to 32 | 16 to 52 | |||||||
iNMB | 95% CrI | iNMB | 95% CrI | iNMB | 95% CrI | iNMB | 95% CrI | iNMB | 95% CrI | ||
Status quo as of April 1, 2022 | 10.2 | 5.3, 15.7 | 1.1 | −4.0, 7.1 | 1.7 | −3.3, 7.8 | −11.0 | −11.9, −10.2 | −9.1 | −10.0, −8.3 | SP1 |
6.4 | 0.9, 11.5 | −1.5 | −6.7, 4.0 | −0.8 | −6.1, 4.7 | −9.5 | −10.4, −8.7 | −8.0 | −8.7, −7.2 | SP2 | |
10.2 | 5.0, 15.9 | 2.0 | −3.0, 7.8 | 2.9 | −2.2, 8.6 | −8.6 | −9.5, −7.7 | −7.1 | −7.9, −6.3 | SP3 | |
20% increase over status quo | 14.3 | 6.4, 21.6 | 5.3 | −2.9, 12.8 | 5.0 | −3.0, 12.3 | −9.5 | −10.7, −8.5 | −8.2 | −9.4, −7.2 | SP1 |
14.1 | 6.4, 21.7 | 7.1 | −0.5, 15.0 | 6.4 | −1.5, 14.1 | −8.7 | −9.9, −7.7 | −6.7 | −7.9, −5.7 | SP2 | |
7.1 | −0.6, 13.9 | 0.4 | −7.3, 7.7 | 0.4 | −7.2, 7.6 | −8.7 | −10.0, −7.7 | −7.3 | −8.6, −6.4 | SP3 | |
80% increase over status quo | 13.8 | 4.7, 22.1 | 7.7 | −0.8, 16.0 | 3.0 | −5.1, 11.2 | −4.8 | −6.6, −3.1 | −8.2 | −10.0, −6.4 | SP1 |
11.8 | 3.3, 20.4 | 7.7 | −0.9, 16.7 | 3.7 | −4.6, 12.8 | −6.6 | −8.0, −5.2 | −9.1 | −10.5, −7.8 | SP2 | |
5.4 | −3.3, 13.7 | 1.1 | −7.3, 9.2 | −2.7 | −11.0, 5.2 | −6.0 | −7.4, −4.6 | −8.8 | −10.1, −7.3 | SP3 | |